Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. tuberculini

Tuberculini SIGNED

A novel in-vitro diagnostic test for drug-resistant tuberculosis and a personalized antibiotic treatment plan.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 Tuberculini project word cloud

Explore the words cloud of the Tuberculini project. It provides you a very rough idea of what is the project "Tuberculini" about.

advice    competitors    uses    commercial    resistance    addressable    platform    followed    tests    vision    personalized    generation    sme    world    patient    dickinson    rapid    minimum    algorithms    global    dna    obtaining    samples    sequencing    competitive    valued    10k    person    disease    companies    becton    company    hours    tuberculini    larger    vs    cepheid    ivds    plan    12    tuberculosis    susceptibility    lifescience    detection    significantly    p1    ag    detect    prescription    analyze    positively    2019    learning    founded    clemedi    antibiotics    2050    diagnostic    diseases    causes    ivd    resistant    primers    mdr    university    caused    profiles    proprietary    tb    death    feasibility    diagnose    spin    battle    24    swiss    antibiotic    inability    hain    advantage    infections    data    drug    48    total    vitro    machine    amplify    zurich    240k    73    annotate    mortalities    contributor    opportunity    infectious    diagnosed    matching    antimicrobial    off    market    smei    therapy    business    ngs    financial    solution   

Project "Tuberculini" data sheet

The following table provides information about the project.

Coordinator		 CLEMEDI AG 

Organization address
address: WAGISTRASSE 12
city: SCHLIEREN
postcode: CH-8952
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CLEMEDI AG CH (SCHLIEREN) coordinator 50˙000.00

Map

 Project objective

Company: Clemedi AG is a Swiss SME, founded in 2019 as a spin-off from the University of Zurich, with the aim to develop in vitro diagnostic (IVD) tests for antibiotic resistance and susceptibility in infectious diseases. The vision of Clemedi is to support the global battle against antibiotic resistance by developing IVDs that will allow personalized prescription of antibiotics.

Need to address: Antimicrobial resistant infections will be among the world’s leading causes of death by 2050. Multi-drug-resistant tuberculosis (MDR-TB) is a large contributor to death by antimicrobial resistance, with over 240k global mortalities (of which 10k in Europe) per year. Many of these are caused by the inability to detect resistance and antibiotic susceptibility in the diagnostic process.

Solution: Clemedi is developing a unique platform to rapidly diagnose drug-resistant infectious diseases, including MDR-TB, and rapidly provide a matching therapy plan. The platform uses proprietary primers to amplify specific DNA from patient samples, followed by next-generation sequencing (NGS) analysis. Machine-learning algorithms are then used to annotate the NGS data, and determine susceptibility or resistance based on DNA-profiles to provide a focused advice on antibiotic therapy, within 24-48 hours after obtaining a patient’s sample.

Business opportunity: The minimum total addressable market for Clemedi (i.e. every person that needs to be diagnosed for MDR-TB) is valued at €73.7 M. Competitors are companies that also develop IVDs for rapid detection of MDR-TB, such as Hain Lifescience, Cepheid and Becton-Dickinson. The main competitive advantage of Tuberculini is its ability to analyze susceptibility for a significantly larger number of antibiotics (12 vs. 1-5). Only this can positively impact disease management.

Feasibility study: Financial support from the SMEi P1 will be used to assess the technical and commercial feasibility of Tuberculini, Clemedi’s IVD for MDR-TB.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TUBERCULINI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TUBERCULINI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

EVERCAM (2020)

Intelligent Vision System for Improved Communication and Higher Productivity in Construction

Read More  

COUNTMITMENT (2019)

NATURAL CAPITAL ACCOUNTANCY TO IMPROVE REPORTING AND ENVIRONMENTAL PERFORMANCE

Read More